GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Anbio Biotechnology NNNN · USD

Health Care · US listing · 🇺🇸 United States

Compare

4.08

+4.88%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Anbio Biotechnology

Its shares trade under the ticker NNNN. It has been listed since 19 February 2025. In the fiscal year to 31 December 2025, it reported revenue of $8.6m and net income of $6.4m. At that date it held total assets of $30.2m and shareholders' equity of $30.2m.

Anbio Biotechnology is a DE-based company operating in Biotechnology industry. The company is headquartered in Frankfurt, Hessen. The company went IPO on 2025-02-19. Anbio Biotechnology is a Germany-based company. The firm is primarily engaged in the manufacturing of In Vitro Diagnostic Substance.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
19 Feb 2025
Employees
27
Head office
FRIEDRICH-EBERT-ANLAGE 49, FRANKFURT AM MAIN, 2M, 60308
Incorporated in
E9
Classification
In Vitro & In Vivo Diagnostic Substances
Filer status
Non-accelerated filer<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Michael LauChief Executive Officer$250,000
  • Ms. Suki SongChief Financial Officer$16,667
  • Mr. Cany XuExecutive Director, since 2023
  • Mr. Chris TiantianChief Business Officer$113,744
  • Ms. Nancy HartzlerIndependent Director
  • Mr. David HsuIndependent Director
  • Mr. Kenneth LiIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Anbio Biotechnology's focus on In Vitro Diagnostic Substance manufacturing in Germany.
  • The company's IPO on 19 February 2025 demonstrates strong market confidence.
  • Operating in the Health Care sector with 27 employees shows agility and specialization.

Weaknesses

  • Limited employee count of 27 may hinder scalability and R&D capacity.
  • The company's small size could limit its ability to compete with larger biotech firms.
  • Dependence on the German market might restrict international growth opportunities.

Opportunities

  • Growing demand for In Vitro Diagnostic Substance in the European Health Care sector.
  • Expansion into the global Health Care market could leverage Germany's biotech reputation.
  • Potential partnerships with major Health Care providers in Europe.

Threats

  • Intense competition from established biotech companies in the Health Care sector.
  • Regulatory changes in the German Health Care industry could impact operations.
  • Economic downturns in Europe might reduce demand for diagnostic substances.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.